Log in to search using one of your social media accounts:

This page shows you the latest items in this publication.

XELJANZ ® (tofacitinib citrate) receives marketing authorisation in the European Union for the treatment of moderate to severe active rheumatoid arthritis
Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) oral tablets in combination with methotrexate (MTX) for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). (Source: World Pharma News)
Source: World Pharma News - March 27, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

TB Alliance sublicenses promising anti-tuberculosis drug from the Medicines Patent Pool
On World Tuberculosis Day, TB Alliance and the Medicines Patent Pool (MPP) announced a licensing agreement for the clinical development of sutezolid, an antibiotic drug candidate which demonstrated encouraging results in early studies. The sublicense pertains to the development of sutezolid in combination with other TB drugs and follows the MPP’s license for the treatment signed with patent holder The Johns Hopkins University in January. (Source: World Pharma News)
Source: World Pharma News - March 24, 2017 Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news

FDA approves first treatment for rare form of skin cancer
The U.S. Food and Drug Administration has granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. This is the first FDA-approved treatment for metastatic MCC, a rare, aggressive form of skin cancer. (Source: World Pharma News)
Source: World Pharma News - March 24, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Major breakthrough in the manufacture of red blood cells
Researchers have generated the first immortalised cell lines which allow more efficient manufacture of red blood cells. The team, from the University of Bristol and NHS Blood and Transplant, were able to manufacture red blood cells in a more efficient scale than was previously possible. The results, published in Nature Communications, could, if successfully tested in clinical trials, eventually lead to a safe source of transfusions for people with rare blood types, and in areas of the world where blood supplies are inadequate or unsafe. (Source: World Pharma News)
Source: World Pharma News - March 23, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Bayer's Rivaroxaban demonstrated superior protection against recurrent venous thromboembolism compared with Aspirin in EINSTEIN CHOICE study
Bayer AG and its development partner Janssen Pharmaceuticals, Inc. have announced results from the EINSTEIN CHOICE study, which demonstrated that both 10 mg and 20 mg once-daily dosages of its oral Factor Xa inhibitor rivaroxaban (Xarelto®) significantly reduced the risk of recurrent venous thromboembolism (VTE) compared with aspirin 100 mg once daily (acetylsalicylic acid, ASA) in patients who had previously completed 6 to 12 months of anticoagulation therapy for pulmonary embolism (PE) or symptomatic deep vein thrombosis (DVT). (Source: World Pharma News)
Source: World Pharma News - March 23, 2017 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

Alzheimer's disease linked to the metabolism of unsaturated fats
A new study published in PLOS Medicine's Special Issue on Dementia has found that the metabolism of omega-3 and omega-6 unsaturated fatty acids in the brain are associated with the progression of Alzheimer's disease. Alzheimer's disease is a neurodegenerative disorder, which causes impaired memory, executive function and language. It accounts for 60 - 80% of total dementia cases worldwide, with over 46 million people suffering from the disease worldwide. (Source: World Pharma News)
Source: World Pharma News - March 23, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis
Novartis has announced new data suggesting, for the first time, that Cosentyx® (secukinumab) may modify the course of moderate-to-severe psoriasis leading to long-term, treatment-free skin clearance[1]. Cosentyx is the first and only IL-17A inhibitor to have reported this potential of disease modification. (Source: World Pharma News)
Source: World Pharma News - March 22, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

FDA approves drug to treat Parkinson's disease
The U.S. Food and Drug Administration has approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson's disease who are currently taking levodopa/carbidopa and experiencing "off" episodes. An "off" episode is a time when a patient’s medications are not working well, causing an increase in Parkinson's symptoms, such as tremor and difficulty walking. (Source: World Pharma News)
Source: World Pharma News - March 22, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Merck Accelerator hits new peak of applications
Merck, a leading science and technology company, announced today the new startups participating in its Accelerator programs in Darmstadt, Germany and Nairobi, Kenya. The two program locations accept startups from different fields within Merck's core specialisms: Darmstadt takes startups from the fields of healthcare, life sciences and performance materials, while Nairobi works exclusively on innovations in digital healthcare. (Source: World Pharma News)
Source: World Pharma News - March 21, 2017 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

First patient cured of rare blood disorder
Using a technique that avoids the use of high-dose chemotherapy and radiation in preparation for a stem cell transplant, physicians at the University of Illinois Hospital & Health Sciences System have documented the first cure of an adult patient with congenital dyserythropoietic anemia. CDA is a rare blood disorder in which the body does not produce enough red blood cells, causing progressive organ damage and early death. (Source: World Pharma News)
Source: World Pharma News - March 21, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

eyeforpharma Philadelphia 2017: Be the trusted healthcare partner #efpPhilly
20 - 21 April 2017, Philadelphia, USA. The democratization of healthcare is real, the healthcare delivery landscape is consolidating fast, and the patient is empowered and the customer in charge. Pharma needs to change and develop along with it. One eyeforpharma Philadelphia. 6 in-depth commercial pharma conferences on the key issues of 2017 and beyond. (Source: World Pharma News)
Source: World Pharma News - March 20, 2017 Category: Pharmaceuticals Tags: Featured Events Source Type: news

New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entresto® (sacubitril/valsartan) tablets improved glycemic control, as assessed by hemoglobin A1c (HbA1c) testing, compared to ACE-inhibitor enalapril[1]. (Source: World Pharma News)
Source: World Pharma News - March 20, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

New 'gene silencer' drug reduce cholesterol by over 50 percent
The findings come from the largest trial yet to test the safety and effectiveness of this kind of therapy. The technique, known as RNA interference (RNAi) therapy, essentially 'switches off' one of the genes responsible for elevated cholesterol. Researchers from Imperial College London and their colleagues, who conducted the trial, say the twice-a-year treatment could be safely given with or without statins, depending on individual patient needs. (Source: World Pharma News)
Source: World Pharma News - March 20, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Landmark outcomes study shows that Repatha ® (Evolocumab) decreases LDL-C to unprecedented low levels and reduces risk of cardiovascular events
Amgen (NASDAQ:AMGN) today announced that the 27,564-patient Repatha® (evolocumab) cardiovascular outcomes study, FOURIER, established for the first time that maximally reducing low-density lipoprotein cholesterol (LDL-C) levels with Repatha, beyond what is possible with the current best therapy alone, leads to a further reduction in major cardiovascular events, including heart attacks, strokes and coronary revascularizations. (Source: World Pharma News)
Source: World Pharma News - March 17, 2017 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

AstraZeneca and Circassia enter strategic collaboration in respiratory disease
AstraZeneca today announced it has entered a strategic collaboration with Circassia Pharmaceuticals plc, a respiratory biopharmaceutical company, for the development and commercialisation of Tudorza and Duaklir* in the US. Tudorza and Duaklir are inhaled respiratory medicines for the treatment of chronic obstructive pulmonary disease (COPD). (Source: World Pharma News)
Source: World Pharma News - March 17, 2017 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Human antibody for Zika virus promising for treatment, prevention
Researchers have determined the structure of a human antibody bound to the Zika virus, revealing details about how the antibody interferes with the infection mechanism - findings that could aid in development of antiviral medications. The new findings also suggest the antibody might be especially effective because a lower concentration than expected is needed to inhibit a key mechanism of infection, making it more potent than previous antibodies studied. (Source: World Pharma News)
Source: World Pharma News - March 16, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Dietary anti-cancer compound may work by influence on cellular genetics
Researchers have discovered one of the reasons why broccoli may be good for your health. They found that sulforaphane, a dietary compound from broccoli that's known to help prevent prostate cancer, may work through its influence on long, non-coding RNAs. This is another step forward in a compelling new area of study on the underlying genetics of cancer development and progression. (Source: World Pharma News)
Source: World Pharma News - March 16, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Johnson & Johnson reports that investigational Ebola vaccine regimen induced durable immune response 1 year after vaccination in Phase 1 study
Johnson & Johnson announced that final Phase 1 clinical trial data published in JAMA: The Journal of the American Medical Association show that Janssen Pharmaceutical Companies' investigational "prime-boost" Ebola vaccine regimen induced a durable immune response in 100 percent of healthy volunteers one year following vaccination. (Source: World Pharma News)
Source: World Pharma News - March 15, 2017 Category: Pharmaceuticals Tags: Featured Johnson & Business and Industry Source Type: news

Drug combination delivered by nanoparticles may help in melanoma treatment
The first of a new class of medication that delivers a combination of drugs by nanoparticle may keep melanoma from becoming resistant to treatment, according to Penn State College of Medicine researchers. CelePlum-777 combines a special ratio of the drugs Celecoxib, an anti-inflammatory, and Plumbagin, a toxin. With the drug, the cells have difficulty overcoming the effect of having more than one active ingredient. (Source: World Pharma News)
Source: World Pharma News - March 15, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Cooking at home tonight? It's likely cheaper and healthier, study finds
Researchers from the University of Washington School of Public Health have been peeking into kitchens - via interviews - for years now. They've just published results showing people who cook at home more often are likely to eat a healthier overall diet. The measurement used to define a healthy diet is called the Healthy Eating Index. It gauges whether a person's diet is giving them the right combination of fruits, vegetables and other elements. (Source: World Pharma News)
Source: World Pharma News - March 14, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

LEO Innovation Lab CEO wins eyeforpharma Customer Innovator Award
LEO Innovation Lab is proud to announce that our CEO Kristian Hart-Hansen has won the eyeforpharma Customer Innovator Award. Kristian has spearheaded the growth of the LEO Innovation Lab since it's conception in 2015 with just six team members, to a thriving incubator of over 80 people and 15 projects today. The lab was established by LEO Pharma as an independent initiative to focus on using digital innovation to help individuals manage chronic skin conditions. (Source: World Pharma News)
Source: World Pharma News - March 14, 2017 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Roche Annual General Meeting 2017
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM). The 855 attending shareholders, representing 86.3% of the total of 160,000,000 shares, approved the Annual Report, the Financial Statements and the Consolidated Financial Statements for 2016. (Source: World Pharma News)
Source: World Pharma News - March 14, 2017 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Phage therapy shown to kill drug-resistant superbug
Scientists from the University of Liverpool have shown that phage therapy could offer a safe and effective alternative to antibiotics in the treatment of Cystic Fibrosis lung infections. Chronic lung infections caused by the bacterium Pseudomonas aeruginosa are becoming increasingly difficult to treat due to antimicrobial resistance (AMR). With limited alternative therapeutic options available this has led to a renewed interest in (bacterio)phage therapy. (Source: World Pharma News)
Source: World Pharma News - March 13, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Sandoz announces winners of inaugural Healthcare Access Challenge #SandozHACk
Sandoz, a Novartis Division, announced today the three winners of the inaugural Healthcare Access Challenge (Sandoz HACk). The winners, chosen by a panel of judges at the Wired Health 2017 event in London, identified innovative approaches to address challenges in Ghana, the Maldives and the Philippines. The winning ideas all proposed novel ways to use mobile technologies to connect patients with caregivers and essential medicines, addressing access issues specific to their country but with the potential for solutions to be applied elsewhere. (Source: World Pharma News)
Source: World Pharma News - March 13, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

New England Journal of Medicine publishes long-term results of Gleevec ®
In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic myeloid leukemia, or CML. The New England Journal of Medicine has published results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent. (Source: World Pharma News)
Source: World Pharma News - March 10, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Researchers identify a new way to promote tissue regeneration
Houston Methodist researchers have identified an immune pathway that promotes the formation of a cell that can develop into new tissues and organs. In a new study published in the journal Stem Cells, a team led by John P. Cooke, M.D., Ph.D., chair of Cardiovascular Sciences, Houston Methodist Research Institute, described how activation of innate immunity enhances nuclear reprogramming, one of the first steps in tissue regeneration, or the formation of new tissues and organs from a single cell in the body. (Source: World Pharma News)
Source: World Pharma News - March 10, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Potential drug candidates halt prostate and breast cancer growth
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have designed two new drug candidates to target prostate and triple negative breast cancers. The new research, published recently as two separate studies in ACS Central Science and the Journal of the American Chemical Society, demonstrates that a new class of drugs called small molecule RNA inhibitors can successfully target and kill specific types of cancer. (Source: World Pharma News)
Source: World Pharma News - March 9, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

The Union for International Cancer Control and Pfizer announce next phase of global grants initiative supporting metastatic breast cancer patients
In conjunction with International Women's Day, The Union for International Cancer Control (UICC) and Pfizer Inc. have announced the next phase of their pioneering grants initiative to address the unique challenges facing metastatic breast cancer (mBC) patients around the globe. (Source: World Pharma News)
Source: World Pharma News - March 9, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Antioxidants and lung cancer risk
An epidemiological study published in Frontiers in Oncology suggests that a diet high in carotenoids and vitamin C may protect against lung cancer. The study authors found that vitamin C appears to reduce the risk of lung cancer in heavy smokers while beta-carotene, alpha-carotene, beta-cryptoxanthin, and lycopene play the same role in male heavy smokers. (Source: World Pharma News)
Source: World Pharma News - March 8, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Boehringer Ingelheim expands collaboration with Vanderbilt University to tackle some of the most difficult-to-treat cancers
Boehringer Ingelheim has announced a new collaboration with Vanderbilt University, Nashville, Tennessee. The multi-year program complements an already existing collaboration by focusing on the research and development of small molecule compounds targeting the protein SOS (Son Of Sevenless). This molecule activates KRAS, a molecular switch that plays a central role in the onset of some of the deadliest cancers. (Source: World Pharma News)
Source: World Pharma News - March 8, 2017 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

MedImmune and Sanofi Pasteur form alliance to develop and commercialise potential next-generation respiratory syncytial virus antibody MEDI8897
MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, have announced an agreement to develop and commercialise MEDI8897 jointly. MEDI8897 is a monoclonal antibody (mAb) for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV), the most prevalent cause of LRTI among infants and young children. (Source: World Pharma News)
Source: World Pharma News - March 7, 2017 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Sulforaphane, a phytochemical in broccoli sprouts, ameliorates obesity
Sulforaphane, a phytochemical contained in broccoli sprouts at relatively high concentrations, has been known to exert effects of cancer prevention by activating a transcription factor, Nrf2 (nuclear factor (erythroid-derived 2)-like 2), which regulates the balance of oxidation - reduction in the cell, and by enhancing anti-oxidation ability of the body and detoxication of chemical compounds taken into the body. (Source: World Pharma News)
Source: World Pharma News - March 7, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
Novartis has announced a new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx® (secukinumab) rapidly regain clear or almost clear skin (Psoriasis Area Severity Index, PASI 90 to 100) following relapse during a treatment pause[1]. The analysis also showed no anti-secukinumab antibodies were observed during retreatment[1]. (Source: World Pharma News)
Source: World Pharma News - March 7, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

How molecular machines may drive the future of disease detection and drug delivery
University of Alberta scientists have pulled into the lead in a race to use nanomachines for improved disease detection and drug delivery in patients. In a study published in Nature Communications, the researchers describe the creation of synthetic DNA motors in living cells. The process - previously only successful in test tubes - demonstrates how DNA motors can be used to accomplish specific and focused biological functions in live cells. (Source: World Pharma News)
Source: World Pharma News - March 6, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Phase III APHINITY study shows Roche's Perjeta ® regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin® and chemotherapy
Roche (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS) have announced positive results from the phase III APHINITY study. The study met its primary endpoint and showed that adjuvant (after surgery) treatment with the combination of Perjeta® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy (Source: World Pharma News)
Source: World Pharma News - March 6, 2017 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Volkswagen's excess emissions will lead to 1,200 premature deaths in Europe
In September 2015, the German Volkswagen Group, the world's largest car producer, admitted to having installed "defeat devices" in 11 million diesel cars sold worldwide between 2008 and 2015. The devices were designed to detect and adapt to laboratory tests, making the cars appear to comply with environmental standards when, in fact, they emitted pollutants called nitric oxides, or NOx, at levels that were on average four times the applicable European test-stand limit. (Source: World Pharma News)
Source: World Pharma News - March 3, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Mutual Recognition promises new framework for pharmaceutical inspections for United States and European Union
The United States and the European Union (EU) completed an exchange of letters to amend the Pharmaceutical Annex to the 1998 U.S.-EU Mutual Recognition Agreement. Under this agreement, U.S. and EU regulators will be able to utilize each other's good manufacturing practice inspections of pharmaceutical manufacturing facilities. (Source: World Pharma News)
Source: World Pharma News - March 3, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Bristol-Myers Squibb expands focus on precision medicine with investment and planned collaboration with GRAIL
Bristol-Myers Squibb Company (NYSE: BMY) announced its equity investment and plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is to detect cancer early when it potentially can be cured. By combining the power of high intensity cancer DNA sequencing, leading edge computer science and large clinical studies into a diagnostic platform, GRAIL aims to (Source: World Pharma News)
Source: World Pharma News - March 2, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Scientists stimulate immune system, stop cancer growth
Researchers at the University of Illinois at Chicago report that increasing expression of a chemical cytokine called LIGHT in mice with colon cancer activated the immune system's natural cancer-killing T-cells and caused primary tumors and metastatic tumors in the liver to shrink. (Source: World Pharma News)
Source: World Pharma News - March 2, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves Odactra for house dust mite allergies
The U.S. Food and Drug Administration today approved Odactra, the first allergen extract to be administered under the tongue (sublingually) to treat house dust mite (HDM)-induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis), in people 18 through 65 years of age. (Source: World Pharma News)
Source: World Pharma News - March 1, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Johnson & Johnson completes acquisition of Abbott Medical Optics
Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott. The all-cash $4.325 billion acquisition was originally announced Sept. 16, 2016, and includes ophthalmic products in three areas of patient care: cataract surgery, laser refractive surgery and consumer eye health. (Source: World Pharma News)
Source: World Pharma News - March 1, 2017 Category: Pharmaceuticals Tags: Featured Johnson & Business and Industry Source Type: news

Inhaler users get about half as much medicine as they should from each puff
Tens of millions of Americans with lung disease use metered-dose inhalers each day, and new studies by Rice University electrical engineers and pulmonologists at Baylor College of Medicine have identified critical errors that are causing many inhaler users to get only about half as much medicine as they should from each puff. (Source: World Pharma News)
Source: World Pharma News - March 1, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves once-daily Qtern (dapagliflozin and saxagliptin) tablets for adults with type-2 diabetes
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily Qtern (10mg dapagliflozin and 5mg saxagliptin) for the treatment of type-2 diabetes. The new medicine is indicated as an adjunct to diet and exercise to improve glycaemic (blood sugar level) control in adults with type-2 diabetes who have inadequate control with dapagliflozin (10mg) or who are already treated with dapagliflozin and saxagliptin. (Source: World Pharma News)
Source: World Pharma News - February 28, 2017 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

DIA EuroMeeting explores the road ahead for drug development in the EU and UK
29 - 31 March 2017, Glasgow, United Kingdom. DIA, (founded as the Drug Information Association) announced critical workshops to be held at the 2017 DIA EuroMeeting. The goal of the annual DIA EuroMeeting has always been to stimulate solutions by bringing together diverse stakeholder perspectives on issues affecting drug development in Europe. (Source: World Pharma News)
Source: World Pharma News - February 28, 2017 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Molecule stops fatal pediatric brain tumor
The scientists have found a molecule that stops the growth of an aggressive pediatric brain tumor. The tumor is always fatal and primarily strikes children under 10 years old. Every year, about 300 children under the age of 10 years old in the U.S. develop a tumor referred to as diffuse intrinsic pontine glioma (DIPG). (Source: World Pharma News)
Source: World Pharma News - February 28, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Bristol-Myers Squibb expands International Immuno-Oncology Network (II-ON)
Bristol-Myers Squibb Company (NYSE:BMY) today announced that Columbia University Medical Center and Peter MacCallum Cancer Centre (Peter Mac) have joined the International Immuno-Oncology Network (II-ON), a global peer-to-peer collaboration between Bristol-Myers Squibb and academia that aims to advance Immuno-Oncology (I-O) science and translational medicine to improve patient outcomes. (Source: World Pharma News)
Source: World Pharma News - February 27, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Alzheimer's drug prescribed off-label could pose risk for some
Donepezil, a medication that is approved to treat people with Alzheimer's disease, should not be prescribed for people with mild cognitive impairment without a genetic test. UCLA School of Nursing researchers discovered that for people who carry a specific genetic variation - the K-variant of butyrylcholinesterase, or BChE-K - donezpezil could accelerate cognitive decline. (Source: World Pharma News)
Source: World Pharma News - February 27, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

CUBE Tech Fair welcomes spectacular speakers
10 - 12 May 2017, Berlin, Germany. CUBE Tech Fair welcomes Brigitte Zypries, Germany's Federal Minister for Economic Affairs and Energy. CUBE is inspired by her work at the Ministry of Economics, in which she places a strong emphasis on advancing the Industry 4.0. She supports startups as well as SMBs (small & medium-sized businesses), where she promotes various financial instruments and network opportunities offered by the BMWi. (Source: World Pharma News)
Source: World Pharma News - February 24, 2017 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Ronald E. Blaylock elected to Pfizer's Board of Directors
Pfizer Inc. has announced the election of Ronald E. Blaylock to its Board of Directors, effective immediately. Mr. Blaylock was also appointed to the Corporate Governance and Science and Technology Committees of Pfizer's Board. (Source: World Pharma News)
Source: World Pharma News - February 24, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Drugs similar to aspirin, ibuprofen could help treat sepsis, study suggests
A potentially life-saving treatment for sepsis has been under our noses for decades in the non-steroidal anti-inflammatory drugs (NSAIDs) most people have in their medicine cabinets, a new University of Colorado Boulder study suggests. Each year more than 1 million people in the United States contract sepsis, an overwhelming immune response to infection. It kills as many as half of those who contract it, sometimes within days, according to the National Institutes of Health. (Source: World Pharma News)
Source: World Pharma News - February 23, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news